BELGRADE, MT / ACCESSWIRE / April 18, 2018 / Xtant Medical Holdings, Inc. (NYSE American: XTNT), a leader in the development of regenerative medicine products and medical devices, announced that it has entered into an agreement with Healthcare International Partners (HIP), in Miramar, Florida for expanding distribution in Latin American markets. The three-year agreement with HIP will focus on executing Xtant Medical's global strategy, supporting current distribution partners, recruiting partners for new markets, and assisting with country specific product registration and commercialization endeavors.

HIP combines the leadership of Luis Abudo and Maggie Morales Perez, both being senior international executives with over 60 years of combined experience in global expansion in the healthcare space related with medical devices, clinical research, pharmaceutical procurement, hospital turnkey projects, and durable medical equipment, with emphasis on Latin America and other Emerging Markets.

''I have had the pleasure of working with Luis Abudo at previous organizations, and have witnessed the exceptional growth he has been able to achieve through his expertise of Latin American markets and his knowledge of the respective medical device industries'' said Carl O'Connell, chief executive officer of Xtant Medical. ''We are thrilled to be launching this Latin American initiative, and look forward to this being the premier partnership of an expanded global focus to come for Xtant.''

Our partnership with HIP will allow Xtant to proliferate current channels, exploit untapped market opportunities, and to enhance the level of customer service we are able to provide internationally. This relationship will provide expansion into strategic Latin America markets for the company. HIP will enhance our distribution network, medical education programs, engagement of key opinion leaders, and will facilitate customer engagement initiatives, which will position the company to achieve sustainable long-term growth in Latin America.

''We are thrilled at the opportunity to expand Xtant Medical's market share in the region, enhance Xtant's distribution network and reach untapped markets,'' said Luis Abudo, Business Development for Healthcare International Partners. ''We will also assist them to protect their intellectual property, brand, and product registrations in each one of the Latin America markets, all critical to guarantee a permanent presence and sustainable long-term growth.''

About Healthcare International Partners

HIP was established in 2009 with the initial objective to assist medical device companies desiring to export to the Caribbean. We have evolved to become the leading Value-Enhancement Partner to our clients. We service global manufacturing companies, including leaders in their respective fields from United States, Europe and Japan. Our expertise includes assisting our client-partners with Regulatory Strategy including product registrations and in-country regulatory hosting, and within Strategic Commercialization including business intelligence, portfolio assessment, brand positioning, channel segmentation, and distributor selection & management. For more information about HIP, please visit www.hip-llc.com.

About Xtant Medical

Xtant Medical develops, manufactures and markets regenerative medicine products and medical devices for domestic and international markets. Xtant Medical products serve the specialized needs of orthopedic and neurological surgeons, including orthobiologics for the promotion of bone healing, implants and instrumentation for the treatment of spinal disease, tissue grafts for the treatment of orthopedic disorders, and biologics to promote healing following cranial, and foot and ankle surgeries. With core competencies in both biologic and non-biologic surgical technologies, Xtant Medical can leverage its resources to successfully compete in global neurological and orthopedic surgery markets. For further information, please visit www.xtantmedical.com.

Important Cautions Regarding Forward-looking Statements

This press release contains certain disclosures that may be deemed forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to significant risks and uncertainties. Forward-looking statements include statements that are predictive in nature, that depend upon or refer to future events or conditions, or that include words such as ''continue,'' ''efforts,'' ''expects,'' ''anticipates,'' ''intends,'' ''plans,'' ''believes,'' ''estimates,'' ''projects,'' ''forecasts,'' ''strategy,'' ''will,'' ''goal,'' ''target,'' ''prospects,'' ''potential,'' ''optimistic,'' ''confident,'' ''likely,'' ''probable'' or similar expressions or the negative thereof. Statements of historical fact also may be deemed to be forward-looking statements. We caution that these statements by their nature involve risks and uncertainties, and actual results may differ materially depending on a variety of important factors, including, among others: the ability to increase revenue; the ability to achieve expected results; the ability to remain competitive; the ability to innovate and develop new products; the ability to engage and retain qualified technical personnel and members of the Company's management team; influence by Company management; the security of our technology systems; government and third-party coverage and reimbursement for Company products; the ability to obtain donors to support the biologic portfolio; the availability of Company facilities; the ability to remain accredited with the American Association of Tissue Banks; the ability to obtain regulatory approvals; government regulations; product liability claims and other litigation to which we may be subjected; product recalls and defects; timing and results of clinical studies; the ability to obtain and protect Company intellectual property and proprietary rights; infringement and ownership of intellectual property; the ability to successfully integrate recent and future business combinations or acquisitions; the ability to use net operating loss carry-forwards to offset future taxable income; the ability to service Company debt; the ability to comply with covenants in the Company's senior credit facility; and other factors. Additional risk factors are listed in the Company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q under the heading ''Risk Factors.'' You should carefully consider the trends, risks and uncertainties described in this document, the Form 10-K and other reports filed with or furnished to the SEC before making any investment decision with respect to our securities. If any of these trends, risks or uncertainties actually occurs or continues, our business, financial condition or operating results could be materially adversely affected, the trading prices of our securities could decline, and you could lose all or part of your investment. The Company undertakes no obligation to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law. All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by this cautionary statement.

Investor Contact

CG CAPITAL
877.889.1972
investorrelations@cg.capital

Company Contact

Xtant Medical
Molly Mason
mmason@xtantmedical.com
Xtant Medical Holdings, Inc.

SOURCE: Xtant Medical Holdings, Inc.